IMMUNE-MEDIATED ENTEROCOLITIS

This adverse event was reported 3681 times

These drugs are most commonly taken by patients reporting IMMUNE-MEDIATED ENTEROCOLITIS:

# Drug Count
0 NIVOLUMAB 1527
1 IPILIMUMAB 1171
2 PEMBROLIZUMAB 1153
3 CARBOPLATIN 567
4 PACLITAXEL 341
5 PACLITAXEL (AIBUMIN-BOUND) 305
6 DURVALUMAB 238
7 PEMETREXED DISODIUM 230
8 ATEZOLIZUMAB 203
9 CILTACABTAGENE AUTOLEUCEL 187
See all common drugs associated with IMMUNE-MEDIATED ENTEROCOLITIS

IMMUNE-MEDIATED ENTEROCOLITIS is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 ENSITRELVIR 1 0.0556
1 TREMELIMUMAB 159 0.0359
2 CILTACABTAGENE AUTOLEUCEL 187 0.0285
3 IPILIMUMAB 1171 0.0267
4 PENPULIMAB 2 0.0204
5 NIVOLUMAB 1527 0.0156
6 ONTRUZANT 8 0.0153
7 ZANIDATAMAB-HRII 1 0.0122
8 NALDEMEDINE 20 0.0120
9 DURVALUMAB 238 0.0110
See all drugs enriched for association with IMMUNE-MEDIATED ENTEROCOLITIS